Based on PubMed | What items should a clinician include in a patient checklist when evaluating a skin rash in someone with head and neck cancer?

A practical, safety‑first checklist for evaluating skin rash in someone with head and neck cancer should cover history, appearance, severity, likely causes (including treatment toxicities), infection risk, and red‑flag features that need urgent action. Because rashes in cancer care can stem from medications, infections, or less commonly severe reactions, a structured approach helps protect the user and guides next steps. ^{[1] [2]}

1) Initial triage and red flags

• Fever, malaise, or hemodynamic instability. Fever or feeling unwell may suggest infection in immunocompromised users and warrants prompt assessment. ^[2]
• Skin pain, tenderness, dusky/target lesions, mucosal involvement, eye pain/redness, or widespread blistering/peeling. These features can indicate severe drug reactions such as Stevens‑Johnson syndrome/toxic epidermal necrolysis, which require emergency care and permanent avoidance of the causative drug. ^[1]
• Pus, spreading redness, or rapidly worsening rash. These changes may reflect secondary infection and need timely evaluation. ^{[3] [4]}

2) Focused history

• Timing: first day noticed, speed of spread, relation to recent treatments or antibiotics. Many cancer drugs produce rash within predictable windows, and onset helps narrow the cause. ^[1]
• Current and recent therapies: chemotherapy (e.g., cisplatin/5‑FU combinations), immunotherapy (e.g., pembrolizumab), targeted agents (e.g., EGFR, BRAF/MEK inhibitors), and radiation fields/dates. Specific classes are tied to characteristic skin toxicities that influence management. ^{[5] [6] [7]}
• Prior radiation to the area. Rash may be worse in previously irradiated skin and needs gentle skin care and sun protection. ^{[5] [8]}
• Previous similar rashes and what helped. Response to prior moisturizers, antihistamines, or steroids guides current care. ^{[3] [4]}
• Infection risks: neutropenia history, central lines, recent skin trauma, or known fungal/bacterial exposures. Impaired immunity increases the chance of skin infections and their spread. ^[2]
• Allergy and drug eruption history. Some antineoplastics cause maculopapular drug rashes, so past reactions raise suspicion. ^[1]
• Symptoms: itch, burn, pain, photosensitivity, mouth sores, eye irritation. Symptom profile helps differentiate acneiform, maculopapular, photosensitive, or mucocutaneous syndromes. ^{[1] [7]}

3) Physical exam elements

• Distribution/location: face, scalp, chest/back, hands/feet, folds, sun‑exposed vs shielded skin, and overlap with prior radiation fields. Patterns such as facial/chest “acneiform” eruptions suggest EGFR‑inhibitor effects, while sun‑exposed flares suggest photosensitivity. ^{[6] [7]}
• Morphology: macules/papules, pustules, plaques, scales, crusts, vesicles/bullae, erosions, or hyperkeratosis. Maculopapular rashes are common with anti‑cancer drugs; pustules point toward acneiform eruptions. ^{[1] [6]}
• Severity grading: estimate body surface area (BSA) involved and impact on function/sleep. Grading drives treatment intensity and whether to modify therapy. ^[1]
• Secondary infection signs: warmth, expanding erythema, purulence, tenderness. Infection superimposed on treatment rash is more likely in immunocompromised users and needs antibiotics. ^[2]
• Nails, hair, and mucosa: periungual redness, nail lifting, oral ulcers, conjunctival involvement. Cancer treatments can affect skin appendages and mucosa and broaden differential and care needs. ^{[9] [1]}

4) Differential diagnosis to consider

• Treatment‑related toxicities
  • Cytotoxic/combination chemotherapy: maculopapular rash, dry itchy skin, peeling or blisters; worse in irradiated areas. Supportive skin care and clinician notification are advised. ^{[5] [8]}
  • Immunotherapy (pembrolizumab): morbilliform rash, pruritus; can rarely become severe and require steroid treatment and therapy hold based on grade. Early recognition prevents progression. ^[10]
  • EGFR inhibitors: acneiform (pustular) rash, often face/chest/back; can be mitigated with moisturizers, sun protection, topical steroids, and oral tetracyclines per severity. Pre‑emptive or reactive regimens reduce severity without routine dose reduction for mild cases. ^[6]
  • BRAF/MEK inhibitors: photosensitivity, hyperkeratosis, papules, secondary skin tumors; strict photoprotection is important. Knowing this profile steers sunscreen and monitoring. ^[7]
• Radiation‑related dermatitis or recall. Previously irradiated skin can flare with systemic therapy, guiding gentle skin care and surveillance. ^[5]
• Infections (bacterial, fungal, viral) in immunocompromised users. Altered skin barrier and immune function increase risks and can lead to dissemination. ^[2]
• Severe cutaneous adverse reactions (SCAR): SJS/TEN spectrum. These are rare but life‑threatening; re‑exposure is contraindicated. ^[1]

5) Severity grading anchors (for clinic use)

• Extent (BSA): limited vs widespread. Larger BSA usually needs stronger therapy and may prompt drug modification. ^[1]
• Symptoms: none/mild itch vs sleep‑disrupting itch/pain. Symptom burden helps classify grade and urgency. ^[1]
• Functional impact: daily activities, adherence to therapy, and self‑care ability. Function guides escalation and supportive resources. ^[1]
• Systemic signs: fever or malaise increase concern for infection or severe reaction. Systemic symptoms push toward urgent evaluation. ^[2]

6) Basic workup when indicated

• If infection suspected: swab cultures from pustules/erosions and consider CBC if febrile or immunosuppressed. Early identification of pathogens helps targeted therapy and is important in immunocompromised care. ^[2]
• If severe/drug reaction suspected: consider dermatology consult and, if uncertain, biopsy for diagnosis. Because different mechanisms can mimic one another in oncology skin eruptions, histology can clarify. ^[11]
• Medication reconciliation and timing charting. Precise correlation of drug timing with rash onset strengthens causal assessment. ^[1]

7) First‑line supportive care for many mild rashes

• Gentle, fragrance‑free moisturizers (e.g., sorbolene or aqueous cream) applied regularly. Hydration of the skin reduces itch and scaling. ^{[5] [8] [12]}
• Avoid scratching or tight clothing; use lukewarm showers and mild cleansers. Mechanical irritation worsens inflammation. ^{[3] [4]}
• Sun protection: SPF 50+, wide‑brim hat, protective clothing, sunglasses; minimize midday sun. Photoprotection is essential, especially with agents that increase photosensitivity. ^{[3] [4] [10] [7]}
• Topical low‑ to mid‑potency steroids for inflammatory rashes and oral antihistamines for itch, as directed by the care team. These measures often relieve symptoms and may prevent progression. ^{[3] [4]}
• For acneiform eruptions with EGFR inhibitors: consider facial/upper‑torso topical regimens and oral tetracyclines per pre‑emptive or reactive algorithms; avoid unnecessary dose reductions for grade 1. Targeted measures improve comfort and adherence. ^[6]

8) When to escalate or modify cancer therapy

• Worsening rash despite supportive care, involvement of large BSA, sleep‑disrupting symptoms, or any mucosal/ocular involvement. These features often require prescription‑strength treatments and may prompt holding or adjusting oncology therapy based on grade. ^[1]
• Signs of infection or systemic illness. Prompt antimicrobial therapy and possible treatment pause may be safer until infection is controlled. ^[2]
• Suspected SCAR (SJS/TEN). Immediate discontinuation of the culprit agent and urgent specialty care are crucial, and the agent should not be re‑introduced. ^[1]

9) Patient education points to include

• How to moisturize and protect skin daily; avoid scratching and tight clothing. Simple skin care reduces irritation and secondary infection risk. ^{[3] [4]}
• Sun safety and clothing; reapplying high‑SPF sunscreen. This is particularly important with photosensitizing regimens. ^{[10] [7]}
• Clear “call your clinic now” list: fever, painful/worsening rash, pus, blisters/peeling, mucosal or eye symptoms, or any rapid change. Early reporting enables timely interventions and prevents complications. ^{[3] [4] [1]}

---

Quick reference table: common treatment‑linked rash patterns and first steps

Treatment class	Typical rash features	First supportive steps	Notes
Cytotoxic combinations (e.g., cisplatin + 5‑FU ± pembrolizumab)	Red/bumpy maculopapular rash; dry, itchy skin; peeling/blisters possible; worse in prior radiation fields	Fragrance‑free moisturizers, avoid scratching/tight clothes, sun protection; consider antihistamines/topical steroids as directed	Monitor closely; tell care team about any change or signs of infection
Immunotherapy (e.g., pembrolizumab)	Morbilliform rash, pruritus; can escalate	As above; escalate to prescription therapy based on grade; consider therapy hold if moderate‑severe	Early recognition helps prevent severe immune‑related events
EGFR inhibitors	Acneiform (pustular) rash on face/chest/back	Emollients, sun protection; topical steroids; consider oral doxycycline/minocycline; pre‑emptive or reactive algorithms	Dose reduction usually not needed for grade 1
BRAF/MEK inhibitors	Photosensitivity, hyperkeratosis, papules; secondary lesions	Strict photoprotection (SPF 50+, clothing), emollients; monitor skin changes	Dermatologic review for suspicious lesions

---

Clinician‑ready checklist (printable)

• Red flags screened (fever, pain, blisters/peeling, mucosal/ocular involvement). ^{[1] [2]}
• Onset and progression charted; relation to each drug cycle and radiation fields. ^{[5] [1]}
• Full medication list (oncology, antibiotics, new OTC/herbals) updated. ^[1]
• Distribution and morphology documented with photos if available; BSA and symptom severity graded. ^[1]
• Infection risk assessed; cultures/CBC ordered when indicated. ^[2]
• Working differential captured: treatment toxicity vs infection vs SCAR vs other dermatoses. ^{[1] [2]}
• Initial supportive care prescribed: emollients, photoprotection, antipruritic plan; EGFR‑specific measures if relevant. ^{[3] [4] [6]}
• Clear return/ESM (early symptom monitoring) instructions added for red‑flag changes. ^{[3] [4]}
• Plan for follow‑up and thresholds for therapy modification documented. Include who to call and when. ^[1]

By integrating these items into a concise, reproducible checklist, clinicians can more reliably distinguish common treatment rashes from infections or rare severe reactions, initiate timely supportive care, and protect continuity of cancer therapy when it is safe to do so. A consistent structure reduces missed red flags and supports patient education and adherence. ^{[1] [2]}